Atypische Antipsychotika in der Therapie der bipolaren affektiven Störung

E. Hilger; C. Barnas

doi:10.1055/s-2002-28431

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000019.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Fortschr Neurol Psychiatr 2002; 70(5): 234-242
DOI: 10.1055/s-2002-28431

Originalarbeit

Atypische Antipsychotika in der Therapie der bipolaren affektiven Störung

Atypical Antipsychotics in the Treatment of Bipolar Affective DisordersE. Hilger¹ , C. Barnas¹

¹Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Wien

Further Information

Publication History

Publication Date:
08 May 2002 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Zusammenfassung

Antipsychotischen Substanzen kommt in der Behandlung bipolarer affektiver Störungen ein bedeutender klinischer Stellenwert zu. Trotz des gut dokumentierten antimanischen Effektes klassischer Antipsychotika ist der Einsatz dieser Substanzen, nicht zuletzt wegen des weitgehenden Fehlens stimmungsstabilisierender Eigenschaften und des erhöhten Risikos für Spätdyskinesien bei affektiven Patienten, mit einer Reihe von Nachteilen verbunden. Mit Entwicklung der neuen, sog. atypischen Antipsychotika ist die Pharmakotherapie der bipolaren Störung um vielversprechende Dimensionen erweitert worden. Gut untersucht wurden die thymoleptischen Eigenschaften von Clozapin, Risperidon und Olanzapin. Für Clozapin und Olanzapin werden ausgeprägtere antimanische als antidepressive Eigenschaften vermutet, Risperidon hingegen dürfte eine stärkere antidepressive als antimanische Wirkkomponente aufweisen. Dieser Artikel bietet einen Überblick über die vorliegenden Studien zur Wirksamkeit atypischer Antipsychotika in der Indikation der bipolaren Störung, darüber hinaus werden mögliche Arzneimittelinteraktionen zwischen Antipsychotika und anderen stimmungsstabilisierenden Pharmaka auf Basis des Cytochrom-P450-Systems diskutiert. Zusammenfassend ist anzunehmen, dass atypische Antipsychotika wertvolle Optionen in der Pharmakotherapie der bipolaren Störung darstellen. Zur Evaluierung des Stellenwertes einzelner Substanzen in dieser Indikation bedarf es jedoch weiterer kontrollierter Untersuchungen.

Abstract

Antipsychotics are commonly used in the treatment of bipolar affective disorder. The use of conventional antipsychotic agents, though effective as antimanic agents, is associated with a number of limitations such as their acute side effect profile and their unsufficient mood stabilizing activity. In addition, exposure to conventional neuroleptics poses a risk for the development of tardive dyskinesia, especially in mood disorder patients. Growing evidence suggests that the novel, so-called atypical neuroleptics may offer a number of advantages in the treatment of bipolar disorder, including their thymoleptic activity and minimal risk for acute and long-term extraypyramidal symptoms. Clinical experience with clozapine and olanzapine as mood stabilizers suggests greater antimanic than antidepressant properties, while risperidone may have greater antidepressant properties with some liability for triggering or exacerbating mania. The mood stabilizing properties of further atypical drugs are currently under investigation. This review focuses on the use of atypical antipsychotics in the treatment of bipolar disorder. We also present an overview concerning potential pharmakokinetic interactions based on the cytochrome P450 enzyme system when antipsychotics are combined with other mood stabilizing compounds. In conclusion, atypical antipsychotics should come to play an increasingly important role in the acute and long-term management of bipolar disorder, but there is a clear need for further controlled trials in this indication.

Literatur

1 Goodwin F K, Jamison K R. Manic-Depressive Illness. New York: Oxford University Press 1990

Search in Google Scholar
2 Prien R F, Gelenberg A J. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry. 1989; 46(7) 840-848

PubMed Search in Google Scholar
3 Post R M, Ketter T A, Denicoff K, Pazzaglia P J, Leverich G S, Marangell L B, Callahan A M, George M S, Frye M A. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology. 1996; 128(2) 115-129

Crossref PubMed Search in Google Scholar
4 Himmelhoch J M, Garfinkel M E. Sources of lithium resistance in mixed mania. Psychopharmacol Bull. 1986; 22(3) 613-620

PubMed Search in Google Scholar
5 Dunner D L, Fieve R R. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974; 30(2) 229-233

Crossref PubMed Search in Google Scholar
6 Gitlin M J, Swendsen J, Heller T L, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995; 152(11) 1635-1640

PubMed Search in Google Scholar
7 Denicoff K D, Smith-Jackson E E, Disney E R, Ali S O, Leverich G S, Post R M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997; 58(11) 470-478

PubMed Search in Google Scholar
8 Sernyak M J, Godleski L S, Griffin R A, Mazure C M, Woods S W. Chronic neuroleptic exposure in bipolar outpatients. J Clin Psychiatry. 1997; 58(5) 193-195

PubMed Search in Google Scholar
9 Sernyak M J, Woods S W. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull. 1993; 29(3) 375-381

PubMed Search in Google Scholar
10 Verdoux H, Gonzales B, Takei N, Bourgeois M. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord. 1996; 38(2 - 3) 81-87

Crossref PubMed Search in Google Scholar
11 Johnson G, Gershon S, Burdock E I, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry. 1971; 119(550) 267-276

PubMed Search in Google Scholar
12 Spring G, Schweid D, Gray C, Steinberg J, Horwitz M. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry. 1970; 126(9) 1306-1310

PubMed Search in Google Scholar
13 Platman S R. A comparison of lithium carbonate and chlorpromazine in mania. Am J Psychiatry. 1970; 127(3) 351-353

PubMed Search in Google Scholar
14 Prien R F, Caffey Jr E M, Klett C J. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1972; 27(2) 182-189

PubMed Search in Google Scholar
15 Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry. 1975; 32(1) 34-42

PubMed Search in Google Scholar
16 McElroy S L, Keck P E, Stanton S P, Tugrul K C, Bennett J A, Strakowski S M. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry. 1996; 57(4) 142-146

PubMed Search in Google Scholar
17 Grossi E, Saccetti E, Vita A. Carbamazepine vs. chlorpromazine in manics: a double blind trial. In: Emrich HM, Okuma T, Muller AA (Eds.) Anticonvulsants in affective disorders Amsterdam, The Netherlands: Excerpta Medica 1984: 177-187

Search in Google Scholar
18 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology. 1979; 66(3) 211-217

Crossref PubMed Search in Google Scholar
19 Janicak P G, Bresnahan D B, Sharma R, Davis J M, Comaty J E, Malinick C. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol. 1988; 8(1) 33-37

PubMed Search in Google Scholar
20 Tohen M, Zarate Jr C A. Antipsychotic agents and bipolar disorder. J Clin Psychiatry. 1998; 59 Suppl 1 38-48

PubMed Search in Google Scholar
21 Ahlfors U G, Baastrup P C, Dencker S J, Elgen K, Lingjaerde O, Pedersen V, Schou M, Aaskoven O. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand. 1981; 64(3) 226-237

PubMed Search in Google Scholar
22 Peselow E D, Fieve R R, Difiglia C, Sanfilipo M P. Lithium prophylaxis of bipolar illness. The value of combination treatment. Br J Psychiatry. 1994; 164(2) 208-214

PubMed Search in Google Scholar
23 Cole J O, Gardos G, Boling L A, Marby D, Haskell D, Moore P. Early dyskinesia-vulnerability. Psychopharmacology. 1992; 107(4) 503-510

PubMed Search in Google Scholar
24 Gardos G, Teicher M H, Lipinski Jr J F, Matthews J D, Morrison L, Conley C, Cole J O. Quantitative assessment of psychomotor activity in patients with neuroleptic-induced akathisia. Prog Neuropsychopharmacol Biol Psychiatry. 1992; 16(1) 27-37

PubMed Search in Google Scholar
25 Davis K L, Berger P A, Hollister L E. Tardive dyskinesia and depressive illness. Psychopharmacol Commun. 1976; 2(2) 125-130

PubMed Search in Google Scholar
26 Rosenbaum A H, Niven R G, Hanson N P, Swanson D W. Tardive dyskinesia: relationship with a primary affective disorder. Dis Nerv Syst. 1977; 38(6) 423-427

PubMed Search in Google Scholar
27 Jeste D V, Wyatt R J. Understanding and treating tardive dyskinesia. New York: Guilford Press 1982

Search in Google Scholar
28 Glenthoj B, Hemmingsen R, Allerup P, Bolwig T G. Intermittent versus continuous neuroleptic treatment in a rat model. Eur J Pharmacol. 1990; 190(3) 275-286

Crossref PubMed Search in Google Scholar
29 Keck Jr P E, McElroy S L, Strakowski S M, Soutullo C A. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry. 2000; 61 Suppl 4 33-8

PubMed Search in Google Scholar
30 Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics. 1984; 25(2) 135-138

PubMed Search in Google Scholar
31 Yassa R, Ghadirian A M, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry. 1983; 44(11) 410-412

PubMed Search in Google Scholar
32 Mukherjee S, Rosen A M, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry. 1986; 43(4) 342-346

PubMed Search in Google Scholar
33 Lal K P, Saxena S, Mohan D. Tardive dystonia alternating with mania. Biol Psychiatry. 1988; 23(3) 312-316

Crossref PubMed Search in Google Scholar
34 Sachdev P S. Depression-dependent exacerbation of tardive dyskinesia. Br J Psychiatry. 1989; 155 253-255

PubMed Search in Google Scholar
35 Wegner J T, Catalano F, Gibralter J, Kane J M. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry. 1985; 42(9) 860-865

PubMed Search in Google Scholar
36 Wegner J T, Kane J M, Weinhold P, Woerner M, Kinon B, Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatry Res. 1985; 16(4) 331-317

Crossref PubMed Search in Google Scholar
37 Hilger E, Kasper S. Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders. Wien Klin Wochenschr. 2000; 112(24) 1031-1038

PubMed Search in Google Scholar
38 Ghaemi S N. New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry. 2000; 61 Suppl 14 33-42

PubMed Search in Google Scholar
39 Brown E S, Thomas N R, Carmody T, Mahadi S, Nejtek V A. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry. 2001; 34(2) 80-81

Thieme Connect PubMed Search in Google Scholar
40 Soares J C. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol. 2000; 15(4) 183-196

PubMed Search in Google Scholar
41 Keck Jr P E, McElroy S L, Strakowski S M. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 1998; 59 Suppl 6 74-81

PubMed Search in Google Scholar
42 Gelenberg A J, Hopkins H S. Antipsychotics in bipolar disorder. J Clin Psychiatry. 1996; 57 Suppl 9 49-52

PubMed Search in Google Scholar
43 Tohen M, Jacobs T G, Feldman P D. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000; 2(2) 261-268

Crossref PubMed Search in Google Scholar
44 Zarate Jr C A, Tohen M, Baldessarini R J. Clozapine in severe mood disorders. J Clin Psychiatry. 1995; 56(9) 411-417

PubMed Search in Google Scholar
45 Frye M A, Ketter T A, Altshuler L L, Denicoff K, Dunn R T, Kimbrell T A, Cora-Locatelli G, Post R M. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord. 1998; 48(2 - 3) 91-104

Crossref PubMed Search in Google Scholar
46 Battegay R, Cotar B, Fleischhauer J, Rauchfleisch U. Results and side effects of treatment with clozapine (leponex R). Compr Psychiatry. 1977; 18(5) 423-428

Crossref PubMed Search in Google Scholar
47 Leppig M, Bosch B, Naber D, Hippius H. Clozapine in the treatment of 121 out-patients. Psychopharmacology (Berl). 1989; 99 77-79

Crossref PubMed Search in Google Scholar
48 Naber D, Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry. 1990; 41(8) 886-890

PubMed Search in Google Scholar
49 Ciapparelli A, Dell'Osso L, Pini S, Chiavacci M C, Fenzi M, Cassano G B. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry. 2000; 61(5) 329-334

PubMed Search in Google Scholar
50 McElroy S L, Dessain E C, Pope Jr H G, Cole J O, Keck Jr P E, Frankenberg F R, Aizley H G, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991; 52(10) 411-414

PubMed Search in Google Scholar
51 Zarate Jr C A, Tohen M, Banov M D, Weiss M K, Cole J O. Is clozapine a mood stabilizer?. J Clin Psychiatry. 1995; 56(3) 108-112

PubMed Search in Google Scholar
52 Suppes T, Rush A J, Webb A, Carmody T, Kraemer H. A one year randomized trial of clozapine vs. usual care in bipolar I patients. Biol Psychiatry. 1996; 39 531

PubMed Search in Google Scholar
53 Calabrese J R, Meltzer H Y, Markovitz P J. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol. 1991; 11(6) 396-397

PubMed Search in Google Scholar
54 Green A I, Tohen M, Patel J K, Banov M, DuRand C, Berman I, Chang H, Zarate Jr C, Posener J, Lee H, Dawson R, Richards C, Cole J O, Schatzberg A F. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000; 157(6) 982-998

Crossref PubMed Search in Google Scholar
55 Kimmel S E, Calabrese J R, Woyshville M J, Meltzer H Y. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry. 1994; 55 Suppl B 91-93

PubMed Search in Google Scholar
56 Calabrese J R, Kimmel S E, Woyshville M J, Rapport D J, Faust C J, Thompson P A, Meltzer H Y. Clozapine for treatment-refractory mania. Am J Psychiatry. 1996; 153(6) 759-764

Crossref PubMed Search in Google Scholar
57 Suppes T, McElroy S L, Gilbert J, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992; 32(3) 270-280

Crossref PubMed Search in Google Scholar
58 Frye M A, Altshuler L L, Bitran J A. Clozapine in rapid cycling bipolar disorder. J Clin Psychopharmacol. 1996; 16(1) 87-90

Crossref PubMed Search in Google Scholar
59 Suppes T, Phillips K A, Judd C R. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry. 1994; 36(5) 338-340

Crossref PubMed Search in Google Scholar
60 Banov M D, Zarate Jr C A, Tohen M, Scialabba D, Wines Jr J D, Kolbrener M, Kim J W, Cole J O. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994; 55(7) 295-300

PubMed Search in Google Scholar
61 Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993; 329(3) 162-167

Crossref PubMed Search in Google Scholar
62 Miller D D. Review and management of clozapine side effects. J Clin Psychiatry. 2000; 61 Suppl 8 14-17

PubMed Search in Google Scholar
63 Denney D, Stevens J R. Clozapine and seizures. Biol Psychiatry. 1995; 37(7) 427-433

Crossref PubMed Search in Google Scholar
64 Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Risch S C, Thrivikraman K V, Lewine R L. Clozapine-induced EEG abnormalities and clinical response to clozapine. J Neuropsychiatry Clin Neurosci. 1995; 7(4) 466-470

PubMed Search in Google Scholar
65 Sajatovic M, DiGiovanni S K, Bastani B, Hattab H, Ramirez L F. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania. Psychopharmacol Bull. 1996; 32(1) 55-61

PubMed Search in Google Scholar
66 Schaffer C B, Schaffer L C. The use of risperidone in the treatment of bipolar disorder. J Clin Psychiatry. 1996; 57(3) 136

PubMed Search in Google Scholar
67 Jacobsen F M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry. 1995; 56(9) 423-429

PubMed Search in Google Scholar
68 Schweitzer I. Does risperidone have a place in the treatment of nonschizophrenic patients?. Int Clin Psychopharmacol. 2001; 16(1) 1-19

PubMed Search in Google Scholar
69 Tohen M, Zarate Jr C A, Centorrino F, Hegarty J I, Froeschl M, Zarate S B. Risperidone in the treatment of mania. J Clin Psychiatry. 1996; 57(6) 249-253

PubMed Search in Google Scholar
70 Roose K, Gelders Y, Heylen S. Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration. Acta Psychiatr Belg. 1988; 88(3) 233-241

PubMed Search in Google Scholar
71 McIntyre R, Young L T, Hasey G, Patelis-Siotis I, Jones B D. Risperidone treatment of bipolar disorder. Can J Psychiatry. 1997; 42(1) 88-90

PubMed Search in Google Scholar
72 Lane H Y, Chiu W C, Chang W H. Risperidone monotherapy for mania and depression. Am J Psychiatry. 1999; 156(7) 1115

PubMed Search in Google Scholar
73 Goodnick P J. Risperidone treatment of refractory acute mania. J Clin Psychiatry. 1995; 56(9) 431-432

PubMed Search in Google Scholar
74 Ghaemi S N, Sachs G S, Baldassano C F, Truman C J. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry. 1997; 42(2) 196-199

PubMed Search in Google Scholar
75 Singh A N, Catalan J. Risperidone in HIV-related manic psychosis. Lancet. 1994; 344(8928) 1029-1030

Crossref PubMed Search in Google Scholar
76 Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry. 1995; 56(11) 514-518

PubMed Search in Google Scholar
77 Licht R W, Bysted M, Christensen H. Fixed-dosed risperidone in mania: an open experimental trial. Int Clin Psychopharmacol. 2001; 16(2) 103-110

PubMed Search in Google Scholar
78 Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol. 1998; 21(3) 176-180

PubMed Search in Google Scholar
79 Ghaemi S N, Sachs G S. Long-term risperidone treatment in bipolar disorder: 6-month follow. Int Clin Psychopharmacol. 1997; 12(6) 333-338

PubMed Search in Google Scholar
80 Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol. 1998; 18(2) 172-174

Crossref PubMed Search in Google Scholar
81 Dwight M M, Keck Jr P E, Stanton S P, Strakowski S M, McElroy S L. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet. 1994; 344(8921) 554-555

Crossref PubMed Search in Google Scholar
82 Keck Jr P E, Wilson D R, Strakowski S M, McElroy S L, Kizer D L, Balistreri T M, Holtman H M, DePriest M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry. 1995; 56(10) 466-470

PubMed Search in Google Scholar
83 Hillert A, Maier W, Wetzel H, Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - a functional approach. Pharmacopsychiatry. 1992; 25(5) 213-217

PubMed Search in Google Scholar
84 Aubry J M, Simon A E, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry. 2000; 61(9) 649-655

Crossref PubMed Search in Google Scholar
85 Lane H Y, Lin Y C, Chang W H. Mania induced by risperidone: dose related?. J Clin Psychiatry. 1998; 59(2) 85-86

PubMed Search in Google Scholar
86 Schnierow B J, Graeber D A. Manic symptoms associated with initiation of risperidone. Am J Psychiatry. 1996; 153(9) 1235-1236

PubMed Search in Google Scholar
87 Tomlinson W C. Respiridone and mania. Am J Psychiatry. 1996; 153(1) 132-133

PubMed Search in Google Scholar
88 Khouzam H R, El-Gabalawi F. Treatment of bipolar I disorder in an adolescent with olanzapine. J Child Adolesc Psychopharmacol. 2000; 10(2) 147-151

PubMed Search in Google Scholar
89 Soutullo C A, Sorter M T, Foster K D, McElroy S L, Keck P E. Olanzapine in the treatment of adolescent acute mania: a report of seven cases. J Affect Disord. 1999; 53(3) 279-283

Crossref PubMed Search in Google Scholar
90 Weisler R H, Ahearn E P, Davidson J R, Wallace C D. Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry. 1997; 9(4) 259-262

Crossref PubMed Search in Google Scholar
91 Goodnick P J, Barrios C A. Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother. 2001; 2(4) 667-680

Crossref PubMed Search in Google Scholar
92 McElroy S L, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, Suppes T, Keck Jr P E, Leverich G S, Kmetz G F, Post R M. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord. 1998; 49(2) 119-122

Crossref PubMed Search in Google Scholar
93 Ananth J. Is olanzapine a mood stabilizer?. Can J Psychiatry. 1999; 44(9) 927-928

PubMed Search in Google Scholar
94 Guille C, Sachs G S, Ghaemi S N. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000; 61(9) 638-642

PubMed Search in Google Scholar
95 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999; 14(6) 339-343

Crossref PubMed Search in Google Scholar
96 Tohen M, Zarate C A, Centorrino F, Hegarty J, Zarate S M. Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. San Diego, California :Annual Meeting of the Amerian Psychiatric Association May 17 - 22, 1997

Search in Google Scholar
97 Sharma V, Pistor L. Treatment of bipolar mixed state with olanzapine. J Psychiatry Neurosci. 1999; 24(1) 40-44

PubMed Search in Google Scholar
98 Zullino D, Baumann P. Olanzapine for mixed episodes of bipolar disorder. J Psychopharmacol. 1999; 13(2) 198

PubMed Search in Google Scholar
99 Ketter T A, Winsberg M E, DeGolia S G, Dunai M, Tate D L, Strong C M. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. J Clin Psychiatry. 1998; 59(2) 83-85

PubMed Search in Google Scholar
100 Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson G D, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000; 57(9) 841-849

Crossref PubMed Search in Google Scholar
101 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G, Petty F, Centorrino F, Wang R, Grundy S L, Greaney M G, Jacobs T G, David S R, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999; 156(5) 702-709

PubMed Search in Google Scholar
102 Sanger T M, Grundy S L, Gibson P J, Namjoshi M A, Greaney M G, Tohen M F. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001; 62(4) 273-281

PubMed Search in Google Scholar
103 Zarate Jr C A, Narendran R, Tohen M, Greaney J J, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry. 1998; 59(1) 24-28

Crossref PubMed Search in Google Scholar
104 Ghaemi S N, Cherry E L, Katzow J A, Goodwin F K. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2000; 2(3) 196-199

Crossref PubMed Search in Google Scholar
105 Fitz-Gerald M J, Pinkofsky H B, Brannon G, Dandridge E, Calhoun A. Olanzapine-induced mania. Am J Psychiatry. 1999; 156(7) 1114

PubMed Search in Google Scholar
106 Lindenmayer J P, Klebanov R. Olanzapine-induced manic-like syndrome. J Clin Psychiatry. 1998; 59(6) 318-319

PubMed Search in Google Scholar
107 Allison D B, Casey D E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62 Suppl 7 22-31

PubMed Search in Google Scholar
108 Harada T, Otsuki S. Antimanic effect of zotepine. Clin Ther. 1986; 8(4) 406-414

PubMed Search in Google Scholar
109 Wolfersdorf M, Konig F, Straub R. Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology. 1994; 29(4) 189-193

PubMed Search in Google Scholar
110 Ghaemi S N, Katzow J J. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry. 1999; 11(3) 137-140

Crossref PubMed Search in Google Scholar
111 Dunayevich E, Strakowski S M. Quetiapine for treatment-resistant mania. Am J Psychiatry. 2000; 157(8) 1341

Crossref PubMed Search in Google Scholar
112 Zarate Jr C A, Rothschild A, Fletcher K E, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000; 61(3) 185-189

PubMed Search in Google Scholar
113 Ghaemi S N. New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry. 2000; 61 Suppl 14 33-42

PubMed Search in Google Scholar
114 McElroy S L, Keck Jr P E. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000; 48(6) 539-557

Crossref PubMed Search in Google Scholar
115 Ketter T A, Flockhart D A, Post R M, Denicoff K, Pazzaglia P J, Marangell L B, George M S, Callahan A M. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995; 15(6) 387-398

Crossref PubMed Search in Google Scholar
116 DeVane C L. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994; 55 Suppl 38-45

PubMed Search in Google Scholar
117 Pollok B. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994; 55 (12) 38-45

PubMed Search in Google Scholar
118 Meyer M C, Baldessarini R J, Goff D C, Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf. 1996; 15(5) 333-346

PubMed Search in Google Scholar
119 Goff D C, Baldessarini R J. Drug interactions with antipsychotic agents. J Clin Psychopharmacol. 1993; 13(1) 57-67

PubMed Search in Google Scholar
120 Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia. 1999; 40 Suppl 10 71-76

PubMed Search in Google Scholar
121 Prior T I, Chue P S, Tibbo P, Baker G B. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999; 9(4) 301-309

PubMed Search in Google Scholar
122 Wong Y W, Yeh C, Thyrum P T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001; 21(1) 89-93

Crossref PubMed Search in Google Scholar
123 Lucas R A, Gilfillan D J, Bergstrom R F. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998; 54(8) 639-643

Crossref PubMed Search in Google Scholar
124 Wilson W H. Do anticonvulsants hinder clozapine treatment?. Biol Psychiatry. 1995; 37(2) 132-133

Crossref PubMed Search in Google Scholar
125 Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Risch S C, Thrivikraman K V, Lewine R L. Clozapine-induced EEG abnormalities and clinical response to clozapine. J Neuropsychiatry Clin Neurosci. 1995; 7(4) 466-470

PubMed Search in Google Scholar
126 Arana G W, Goff D C, Friedman H, Ornsteen M, Greenblatt D J, Black B, Shader R I. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?. Am J Psychiatry. 1986; 143(5) 650-651

PubMed Search in Google Scholar
127 Kahn E M, Schulz S C, Perel J M, Alexander J E. Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990; 10(1) 54-57

Crossref PubMed Search in Google Scholar
128 Centorrino F, Baldessarini R J, Flood J G, Kando J C, Frankenburg F R. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry. 1995; 152(4) 610-612

PubMed Search in Google Scholar
129 Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine?. Pharmacopsychiatry. 1993; 26(6) 262

Thieme Connect PubMed Search in Google Scholar
130 Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994; 16(4) 368-374

PubMed Search in Google Scholar
131 Raitasuo V, Lehtovaara R, Huttunen M O. Carbamazepine and plasma levels of clozapine. Am J Psychiatry. 1993; 150(1) 169

PubMed Search in Google Scholar
132 Bourgeois B FD. Pharmacological interactions between valproate and other drugs. Am J Med. 1988; 84 9-33

PubMed Search in Google Scholar
133 Balfour J A, Bryson H M. Valproid acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs. 1994; 2 144-173

PubMed Search in Google Scholar
134 Kando J C, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry. 1994; 55(6) 255-257

PubMed Search in Google Scholar
135 Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry. 1994; 36(7) 487-488

PubMed Search in Google Scholar
136 Centorrino F, Baldessarini R J, Kando J, Frankenburg F R, Volpicelli S A, Puopolo P R, Flood J G. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994; 151(1) 123-125

Crossref PubMed Search in Google Scholar
137 Emrich M, Okuma T, Muller A A. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica 1984

Search in Google Scholar
138 Loudon J B, Waring H. Toxic reactions to lithium and haloperidol. Lancet. 1976; 2(7994) 1088

PubMed Search in Google Scholar
139 Jeffries J, Remington G, Wilkins J. The question of lithium/neuroleptic toxicity. Can J Psychiatry. 1984; 29(7) 601-604

PubMed Search in Google Scholar
140 Goldney R D, Spence N D. Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry. 1984; 29 601-604

PubMed Search in Google Scholar
141 Schou M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand. 1984; 70(6) 594-602

Crossref PubMed Search in Google Scholar
142 Addonizio G, Susman V L, Roth S D. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987; 22(8) 1004-1020

Crossref PubMed Search in Google Scholar
143 Blake L M, Marks R C, Luchins D J. Reversible neurologic symptoms with clozapine and lithium. J Clin Psychopharmacol. 1992; 12(4) 297-299

PubMed Search in Google Scholar
144 Baldessarini R J, Stephens J H. Lithium carbonate for affective disorders. I. Clinical pharmacology and toxicology. Arch Gen Psychiatry. 1970; 22(1) 72-77

PubMed Search in Google Scholar
145 Garcia G, Crismon M L, Dorson P G. Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol. 1994; 14(6) 426-428

PubMed Search in Google Scholar
146 Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol. 1999; 9 Suppl 4 119-123

Crossref PubMed Search in Google Scholar
147 Normann C, Langosch J, Schaerer L O, Grunze H, Walden J. Treatment of acute mania with topiramate. Am J Psychiatry. 1999; 156(12) 2014

PubMed Search in Google Scholar
148 Ketter T A, Frye M A, Cora-Locatelli G, Kimbrell T A, Post R M. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol. 1999; 19(4) 511-532

Crossref PubMed Search in Google Scholar
149 Patsalos P N, Duncan J S. New antiepileptic drugs: a review of their current status and clinical potential. CNS Dugs. 1994; 2 40-77

PubMed Search in Google Scholar
150 Anderson G D, Graves N M. Drug interactions with anti-epileptic agents. Prevention and management. CNS Drugs. 1994; 2 268-279

PubMed Search in Google Scholar
151 Alldredge B K. Seizure risk with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology. 1999; 53 (Suppl. 2) 68-75

PubMed Search in Google Scholar
152 Sproule B A, Naranjo C A, Brenmer K E, Hassan P C. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997; 33(6) 454-471

Crossref PubMed Search in Google Scholar

Prof. Dr. Ch. Barnas

Klinische Abteilung für Allgemeine Psychiatrie · Univ.-Klinik für Psychiatrie

Währinger Gürtel 18-20

1090 Wien

Österreich